Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + lenvatinib + etoposide + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Iparomlimab + tuvonralimab + lenvatinib + EP/EC is an investigational combination regimen being evaluated for the first-line treatment of unresectable or metastatic extrapulmonary neuroendocrine carcinoma (EP-NEC). The regimen's immunotherapy backbone, QL1706 (also known as Qibeian), is a bifunctional combination of two monoclonal antibodies: iparomlimab (targeting PD-1) and tuvonralimab (targeting CTLA-4) in a fixed 2:1 ratio. This is combined with lenvatinib, a multi-kinase inhibitor targeting VEGFR and FGFR, and standard platinum-etoposide chemotherapy (etoposide plus either cisplatin or carboplatin). The combination aims to enhance anti-tumor activity by simultaneously blocking multiple immune checkpoints, inhibiting angiogenesis and tumor cell proliferation, and inducing cytotoxic cell death.
- Brand names
- Qibeian
- Other names
- iparomlimab + tuvonralimab injection + lenvatinib + EP/ECQL1706 + lenvatinib + etoposide + platinum
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)TOP2A (DNA topoisomerase II)FGFR3 (Fibroblast growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + lenvatinib + etoposide + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + lenvatinib + etoposide + cisplatin + carboplatin.